Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial
G Raghu, J Behr, KK Brown, JJ Egan… - Annals of internal …, 2013 - acpjournals.org
Annals of internal medicine, 2013•acpjournals.org
Chinese translation This article has been corrected. The original version (PDF) is appended
to this article as a Supplement. Background: Idiopathic pulmonary fibrosis (IPF) is
characterized by formation and proliferation of fibroblast foci. Endothelin-1 induces lung
fibroblast proliferation and contractile activity via the endothelin A (ETA) receptor. Objective:
To determine whether ambrisentan, an ETA receptor–selective antagonist, reduces the rate
of IPF progression. Design: Randomized, double-blind, placebo-controlled, event-driven …
to this article as a Supplement. Background: Idiopathic pulmonary fibrosis (IPF) is
characterized by formation and proliferation of fibroblast foci. Endothelin-1 induces lung
fibroblast proliferation and contractile activity via the endothelin A (ETA) receptor. Objective:
To determine whether ambrisentan, an ETA receptor–selective antagonist, reduces the rate
of IPF progression. Design: Randomized, double-blind, placebo-controlled, event-driven …
Chinese translation
This article has been corrected. The original version (PDF) is appended to this article as a Supplement.
Background
Idiopathic pulmonary fibrosis (IPF) is characterized by formation and proliferation of fibroblast foci. Endothelin-1 induces lung fibroblast proliferation and contractile activity via the endothelin A (ETA) receptor.
Objective
To determine whether ambrisentan, an ETA receptor–selective antagonist, reduces the rate of IPF progression.
Design
Randomized, double-blind, placebo-controlled, event-driven trial. (ClinicalTrials.gov: NCT00768300)
Setting
Academic and private hospitals.
Participants
Patients with IPF aged 40 to 80 years with minimal or no honeycombing on high-resolution computed tomography scans.
Intervention
Ambrisentan, 10 mg/d, or placebo.
Measurements
Time to disease progression, defined as death, respiratory hospitalization, or a categorical decrease in lung function.
Results
The study was terminated after enrollment of 492 patients (75% of intended enrollment; mean duration of exposure to study medication, 34.7 weeks) because an interim analysis indicated a low likelihood of showing efficacy for the end point by the scheduled end of the study. Ambrisentan-treated patients were more likely to meet the prespecified criteria for disease progression (90 [27.4%] vs. 28 [17.2%] patients; P = 0.010; hazard ratio, 1.74 [95% CI, 1.14 to 2.66]). Lung function decline was seen in 55 (16.7%) ambrisentan-treated patients and 19 (11.7%) placebo-treated patients (P = 0.109). Respiratory hospitalizations were seen in 44 (13.4%) and 9 (5.5%) patients in the ambrisentan and placebo groups, respectively (P = 0.007). Twenty-six (7.9%) patients who received ambrisentan and 6 (3.7%) who received placebo died (P = 0.100). Thirty-two (10%) ambrisentan-treated patients and 16 (10%) placebo-treated patients had pulmonary hypertension at baseline, and analysis stratified by the presence of pulmonary hypertension revealed similar results for the primary end point.
Limitation
The study was terminated early.
Conclusion
Ambrisentan was not effective in treating IPF and may be associated with an increased risk for disease progression and respiratory hospitalizations.
Primary Funding Source
Gilead Sciences.
acpjournals.org